Menu
🇧🇪
In 2018, in the innovative city of Ghent, an entrepreneurial journey unfolded – the incorporation of MyNEO, catalyzed by the vision of seasoned biotech pioneers Jan and Wim, alongside the ambition of Cedric, a driven graduated student. What commenced as an aspiration to build a novel bioinformatics platform swiftly evolved into a journey of exploration and innovation.
The founding team embarked on the development of a bioinformatics platform for personalized immunotherapies, assisting tier 1 pharma companies to navigate the intricacies of their own immunotherapeutic advancements. Their pursuit of innovation and the performance of their discovery engine unearthed a novel class of antigen targets found within the dark part of the genome – Camyotopes.
This pivotal discovery spurred a re-evaluation of the company’s purpose and mission. Transitioning from a service provider within the pharmaceutical sphere, MyNEO is now emerging as a force in the area of therapeutic development. Their research attained prominence in various medical journals, while their intellectual property portfolio is continuing to grow.
At the heart of their in-house development lies: Camyo-01, the most promising program. However, the Camyotopes discovery identified a whole array of molecules, for which the company is now in talks to out-license these development tracks and cultivate strategic alliances with Tier 1 pharmaceutical companies.
Next to that, the company has won many international prizes such as Most Disruptive Innovator, Forbes 30under30 and a spot in the Top 150 Digital Health Company Worldwide.
With the backing of TCD Capital, MyNEO is continuing their journey as a disruptor in the field of oncology.
News articles:
TCD Capital is a fund manager based in Brussels and Antwerp investing in Scale-Ups primarily in Smart Living, Tech, and Life Sciences.
Tenez-vous informé de nos dernières activités en vous inscrivant à notre newsletter.
Nous cherchons à personnaliser le contenu en fonction des segments que nous servons.
Il s'agit à la fois des investisseurs du fonds et des entrepreneurs avec lesquels nous avons créé des alliances.
Nous sommes heureux de rester en contact.
